Researchers at the KU Leuven Rega Institute and CD3 have developed an ultrapotent inhibitor of the dengue virus, which causes the tropical disease known as dengue. The teams collaborated closely with Janssen Pharmaceutica, N.V. The antiviral molecule is exceptionally effective against all known dengue variants and could be used for therapeutic and prevention purposes.
The teams have published their findings in Nature.
Each year, dengue infects up to 400 million people, sickens up to 100 million, and kills thousands. Symptoms of the disease include a high fever and severe muscle and joint pain. Some patients also suffer from subcutaneous bleeding or capillary leakage.
The disease is caused by the mosquito-borne dengue virus, which is found in nearly all (sub)tropical regions, but especially in Latin America and Asia. The frequency of outbreaks continues to grow, and the virus is expected to impact billions more in the coming decades as the virus spreads to other regions due to climate change and other global trends. In 2019, the World Health Organization already included dengue in its list of ten threats to global health.
No antiviral drugs are currently available to prevent or treat dengue. This may change thanks to the breakthrough discovery of teams led by Johan Neyts (Rega Institute at KU Leuven) and Patrick Chaltin (CD3/CISTIM Leuven vzw), which was carried forward in collaboration with Marnix van Loock and team at our strategic partner Janssen Pharmaceutica, N.V.
Blocking the ‘copier’ of the virus
The antiviral has a unique mechanism, explains Professor Johan Neyts of the Rega Institute at KU Leuven. “Together with the research group of Professor Ralf Bartenschlager from Heidelberg University, we demonstrated that our inhibitor prevents the interaction between two viral proteins that are part of a kind of copier for the genetic material of the virus. If this interaction is blocked, the virus can no longer copy its genetic material. As a result, no new virus particles are produced.”
The optimisation process involved about 2000 steps. Years of intensive collaboration have now resulted in an ultra-potent dengue inhibitor that we are proud to present.
– Patrick Chaltin (CD3)
Together with Professor Xavier de Lamballerie (Aix-Marseille University), the team proved that the antiviral is very effective against all known variants of the dengue virus.
The researchers tested the inhibitor in mice as well. Suzanne Kaptein (Rega Institute at KU Leuven): “Even a low dose of the drug administered via the oral route proved to be very effective. What is more, the treatment is still effective when the infection is already at its peak. In these cases, the number of virus particles in the blood dropped drastically within 24 hours after the start of the treatment. This goes to show how extremely potent the antiviral drug is.”
Also suitable for prevention
Research in mice suggests that the inhibitor could also be used for prevention purposes. These findings are cause for optimism, as the existing dengue vaccine only offers partial protection.
Professor Johan Neyts (KU Leuven): “Potent and safe dengue drugs that can be easily taken as tablets could offer anyone effective protection for a certain period of time. Think of people living in areas with an ongoing dengue outbreak, for instance: they could take a dengue drug for a couple of days or weeks. The tablets could also protect travellers or NGO workers during their stay in high-risk regions.”
The antiviral drug will be developed in an easy-to-administer formulation that can be optimised for the treatment and prevention of the disease in dengue-endemic tropical and subtropical regions. ??????
Search of many years
The development of the antiviral was a long haul, says Professor Johan Neyts (KU Leuven). “We started this project in 2009. First, we examined many thousands of molecules in a compound library of the Centre for Drug Design and Discovery (CD3) to find one or more molecules that inhibit the virus in lab-grown cells. In other words: we started looking for a needle in a haystack. As soon as we were able to identify such molecules, the medicinal chemists at CD3 could start to work with them. They created many versions of the molecules to boost their efficacy against the virus.”
There are four types of dengue viruses, and the molecule needed to be equally effective against all four of them, adds Patrick Chaltin from the Centre for Drug Design and Discovery. “It was no easy feat to reach that goal: the optimisation process involved about 2000 steps. Years of intensive collaboration have now resulted in an ultra-potent dengue inhibitor that we are proud to present.”
Original Article: KU Leuven develops very potent antiviral against dengue
The Latest on: Dengue fever
- COVID subsides but Dengue riseson October 16, 2021 at 7:54 pm
Generally after the monsoon takes leave for the next year, chances of mosquitoes infecting people increase and the most complicated but generally curable ...
- 183 more hospitalized with dengue fever in 24 hrson October 16, 2021 at 7:48 pm
As many as 183 people with dengue fever were admitted to different hospitals in and outside the capital in the last 24 hours until Saturday morning. With this, a total of 869 patients diagnosed with ...
- Dengue case count crosses 1,000-mark in Amritsar districton October 16, 2021 at 7:08 pm
The dengue count in the district has reached 1,029 with 379 new cases reported by the Health Department in the last four days. Also the number of patients undergoing treatment at private hospitals or ...
- Pakistan: Punjab dengue cases rise at alarming rate, Lahore reports all four strainson October 16, 2021 at 6:51 pm
By NewsDesk @bactiman63 In a follow-up on the dengue outbreak in Pakistan, health officials in Punjab province in eastern Pakistan report dengue fever cases are rising at an alarming rate. Today, ...
- Surge in Dengue cases: Separate 50-bed ward set up at Mohali hospitalon October 16, 2021 at 6:34 pm
In view of the increasing number of dengue cases, a separate 50-bed ward has been set up in District Hospital in Mohali.
- Understanding Dengue Feveron October 16, 2021 at 12:29 pm
Dr. Tasaduk Hussain Itoo Dengue fever is a viral infection transmitted by two specific types of mosquitoes, the Aedes aegypti and the Aedes albopictus ...
- Dengue Antibody Prevalence in German Travelerson October 16, 2021 at 6:21 am
We studied 2,259 German citizens after they returned from dengue-endemic countries from 1996 to 2004. Serotype-specific dengue antibodies indicated acute infections in 51 (4.7%) travelers with recent ...
- Country reports alarming spike in dengue fever caseson October 15, 2021 at 4:49 pm
ISLAMABAD: Dengue fever across the country is spiking at an alarming rate, especially, in the rural areas, as countrywide 16,330 dengue cases have been recorded, of which 40 people have lost their ...
- Dengue fever: Cases cross 21,000-mark, 106 hospitalised in a dayon October 15, 2021 at 5:41 am
At least 106 patients were hospitalised in 24 hours preceding 8am today. of them 15 cases were from outside Dhaka, according to the Directorate General of Health Services (DGHS).
- No let-up in dengue fever caseson October 14, 2021 at 11:25 pm
RAWALPINDI: Dengue cases are on the rise in Rawalpindi, with the total climbing up to 957. At least 150 individuals have been admitted to three hospitals, with 249 beds arranged s ...
via Bing News
The Latest on: Dengue fever
via Google News